SESSION ONE: OPENING PRESENTATION

This session is of the following presentations:

Opening remarks
Dr Louise Sweeney, Consultant Medical Microbiologist, Manchester University NHS Foundation TrustMr David Glover, Assistant Director of Medicines Analysis, Medicines Policy and Analysis Unit, Commercial Medicines Directorate, NHS England and NHS Improvement & Professor Philip Howard OBE, AMR Regional Antimicrobial Stewardship Lead, NHS England & NHS Improvement – North-East & Yorkshire, UK and immediate Past President, BSAC

Q&A

SESSION TWO: WHAT’S NEW ?

This session is of the following presentations:

CNS Infections – hospital and community acquired Gram-negative Meningitis
Dr Fiona McGill, Consultant in Infectious Diseases and Medical Microbiology, Leeds Teaching Hospitals NHS Trust

EUCAST in practice
Dr Mandy Wootton, Consultant Scientist/Operational Manager, Specialist Antimicrobial Chemotherapy Unit (SACU), Public Health Wales

Diagnostic driven strategies (including TDM and all techniques to drive practice)
Professor Jason Roberts, Clinical Pharmacist, Royal Brisbane and Women’s Hospital & Australian National Health and Medical Research Council Practitioner Fellow, The University of Queensland

Q&A

SESSION THREE: GRAM-NEGATIVE & AMR

This session is of the following presentations:

Resistance mechanisms treatment strategy
Mrs Frances Garraghan, Specialist Antimicrobial Stewardship Pharmacist, Manchester University NHS Foundation Trust

Management of Gram negative infection in patients requiring Extracorporeal Membrane Oxygenation (ECMO).
Dr Stephanie Thomas, Manchester University NHS Foundation Trust

Managing resistant Gram-negative infections in children and the role of novel antimicrobials
Dr Surjo De, Consultant Medical Microbiologist, Great Ormond Street Hospital for Children NHS Foundation Trust 

Q&A

SESSION FIVE: DEBATE – AMS vs. IPC to control AMR (the pros & cons)

This session is of the following presentations:

Pro AMS perspective
Dr Stuart Bond, Consultant antimicrobial pharmacist, Director of Innovation, Mid Yorkshire Hospitals NHS Trust & Visiting fellow, School of Applied Sciences, University of Huddersfield

Pro IPC perspective
Dr Jessica Martin, Consultant Microbiologist, Leeds

Discussion

SESSION SIX: KEYNOTE PRESENTATION

This session is of the following presentations:

Duration of antibiotic therapy for Gram-negative
Dr Brad Spellberg, Chief Medical Officer, Los Angeles County-University of Southern California (LAC+USC) Medical Center

Q&A

SESSION SEVEN: WHAT DOES THE FUTURE LOOK LIKE? IMPROVING GRAM-NEGATIVE TREATMENTS

This session is of the following presentations:

UK Antimicrobial Registry – providing real world data on use of new antimicrobials
Dr Jacqueline Sneddon, Programmes Manager, British Society for Antimicrobial Chemotherapy (BSAC)

Best Practice Recommendations
Dr Luke Moore, Consultant Infectious Diseases, Microbiology, & Virology, Chelsea & Westminster NHS Foundation Trust, Consultant Microbiology, North West London Pathology, Imperial College Healthcare NHS Trust, Honorary Clinical Senior Lecturer, Imperial College London

Non-pharmacological therapies – an overview
Dr Erin Duffy, Chief of Research & Development, CARB-X

Q&A

Closing Remarks
Mrs Frances Garraghan, Specialist Antimicrobial Stewardship Pharmacist, Manchester University NHS Foundation Trust